These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38374309)

  • 1. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
    Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
    Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
    Dodin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
    Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
    Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor of Differentiation-1 Sustains Mutant
    Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
    Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
    Li HS; Liu CM; Wang Y
    Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma.
    Bian Y; Bi G; Shan G; Liang J; Sui Q; Hu Z; Wang Q; Zhang Y; Fan H
    J Immunol Res; 2023; 2023():4987832. PubMed ID: 36793588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 10. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
    Dai D; Shi R; Han S; Jin H; Wang X
    Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
    Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
    J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
    Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
    EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.
    Yang IS; Kim S
    BMC Bioinformatics; 2018 Feb; 19(Suppl 1):40. PubMed ID: 29504894
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
    Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
    [No Abstract]   [Full Text] [Related]  

  • 16. KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.
    Gallina FT; Marinelli D; Melis E; Forcella D; Taje R; Buglioni S; Visca P; Torchia A; Cecere FL; Botticelli A; Santini D; Ciliberto G; Cappuzzo F; Facciolo F
    Lung Cancer; 2023 Jul; 181():107254. PubMed ID: 37253296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
    Wang Q; Tang Z; Li C; Li X; Su C
    Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.